Infectious Diseases and Therapy · 2022 · 10 citations · 16 references
Veterinary MedicineImmunologyInfectious DiseasesDiagnostic MicrobiologyMolecular VirologyVirologyInfectious Disease DetectionRespiratory InfectionsRespiratory Infectious DiseasesRespiratory Pathogen DiagnosticsRespiratory Tract InfectionsViral DiagnosticsCoronavirus DiagnosticsInfluenza DiagnosticsMolecular Respiratory Pathogen DetectionNasal Swab CollectionRespiratory Pathogen ScreeningRespiratory Pathogen TestingSars-cov-2 InfectionTreatment Strategies
INTRODUCTION: Coronavirus disease 2019 (COVID-19) and influenza share similar symptoms, which hampers diagnosis. Given that they require different containment and treatment strategies, fast and accurate distinction between the two infections is needed. This study evaluates the sensitivity and specificity of the microfluidic antigen LumiraDx SARS-CoV-2 and Flu A/B Test for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A/B from a single nasal swab. METHODS: Nasal samples were collected from patients as part of the ASPIRE (NCT04557046) and INSPIRE (NCT04288921) studies at point-of-care testing sites in the USA. ASPIRE study participants were included after developing COVID-19 symptoms in the last 14 days or following a positive SARS-CoV-2 test in the last 48 h. INSPIRE study participants were included after developing influenza symptoms in the last 4 days. Samples were extracted into proprietary buffer and analysed using the LumiraDx SARS-CoV-2 and Flu A/B Test. A reference sample was taken from each subject, placed into universal transport medium and tested using reference SARS-CoV-2 and influenza reverse transcription polymerase chain reaction (RT-PCR) tests. The test and reference samples were compared using the positive percent agreement (PPA) and negative percent agreement (NPA), together with their 95% confidence intervals (CIs). RESULTS: Analysis of the data from the ASPIRE (N = 124) and INSPIRE (N = 159) studies revealed high levels of agreement between the LumiraDx SARS-CoV-2 and Flu A/B Test and the reference tests in detecting SARS-CoV-2 (PPA = 95.5% [95% CI 84.9%, 98.7%]; NPA = 96.0% [95% CI 90.9%, 98.3%]), influenza A (PPA = 83.3% [95% CI 66.4%, 92.7%]; NPA = 97.7% [95% CI 93.4%, 99.2%]) and influenza B (PPA = 80.0% [95% CI 62.7%, 90.5%]; NPA = 95.3% [95% CI 90.2%, 97.9%]). CONCLUSIONS: The LumiraDx SARS-CoV-2 and Flu A/B Test shows a high agreement with the reference RT-PCR tests while simultaneously detecting and differentiating between SARS-CoV-2 and influenza A/B. TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT04557046 and NCT04288921.
16
Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
Lei Bai, Yongliang Zhao, Jiazhen Dong et al. · Cell Research · 2021 · 301 citations · Full text
Coronavirus seasonality, respiratory infections and weather
Gordon Nichols, Emma L. Gillingham, Helen L. Macintyre et al. · BMC Infectious Diseases · 2021 · 101 citations · Full text
Hsing‐Yi Chung, Ming‐Jr Jian, Chih-Kai Chang et al. · Emerging Microbes & Infections · 2021 · 99 citations · Full text
Veterinary Medicine, Infectious Diseases, Molecular Biology +17